Novel dimeric dual-modality FAP-targeted agents with favorable tumor retention for image-guided surgery: a preclinical study
In this study we introduced and evaluated novel dimeric FAP-targeting agents for dual-modality applications. In the preclinical setting, within the group of compounds investigated, two candidates enabled tumor visualization through PET, SPECT and optical imaging, providing satisfactory background contrast after a single administration and supporting their potential for preoperative nuclear imaging and subsequent fluorescence-guided surgery.
Authors
- Kateřina Bendová (ORCID: https://orcid.org/0000-0001-6681-0100)
- Clemens Decristoforo (ORCID: https://orcid.org/0000-0003-0566-4036)
- Kai K. Kummer (ORCID: https://orcid.org/0000-0002-5854-6503)
- Bradley D. Smith (ORCID: https://orcid.org/0000-0003-4120-3210)
- Giacomo Gariglio (ORCID: https://orcid.org/0000-0002-5192-3839)
- Barbara Matuszczak (ORCID: https://orcid.org/0000-0002-4507-8739)
- Zbyněk Nový (ORCID: https://orcid.org/0000-0002-7716-2142)
- Miloš Petřík (ORCID: https://orcid.org/0000-0003-1334-5916)
- Christine Rangger
- Thomas Hasenöhrl
Institutions
- University of Notre Dame (US)
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
- University Hospital Olomouc (CZ)
- Regional Centre of Advanced Technologies and Materials (CZ)
- Institute of Molecular and Translational Medicine (CZ)
- Palacký University Olomouc (CZ)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-11-19
- DOI
- https://doi.org/10.1007/s00259-025-07626-z
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00